The Instituto Português de Oncologia Francisco Gentil, also known as the Instituto Português de Oncologia, Portuguese for Portuguese Oncology Institute, is a state-run cancer hospital and research organization in Portugal. The I.P.O. has autonomous regional branches in Lisbon, Porto and Coimbra.

During the past decade, Instituto Portugues de Oncologia de Francisco Gentil conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 21 clinical trials were completed, i.e. on average, 52.5% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 15 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Portugues de Oncologia de Francisco Gentil" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 24 trials, followed by "Celgene" with 14 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "European Infant Neuroblastoma Study Group - 1999" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Portugues de Oncologia de Francisco Gentil" #1 collaborator was "NCIC Clinical Trials Group" with 6 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 5 trials as a collaborator, "Australian & New Zealand Children's Haematology/Oncology Group" with 2 trials as a collaborator, "Centre Hospitalier Universitaire de Nice" with 2 trials as a collaborator and "Lymphoma Trials Office" with 2 trials as a collaborator. Other collaborators include 78 different institutions and companies that were collaborators in the rest 80 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Portugues de Oncologia de Francisco Gentil" are "Multiple Myeloma" (8 trials), "Neuroblastoma" (7 trials), "Brain and Central Nervous System Tumors" (6 trials), "Melanoma (Skin)" (5 trials) and "Lymphoma" (4 trials). Many other conditions were trialed in "Instituto Portugues de Oncologia de Francisco Gentil" in a lesser frequency.

Most popular intervention types in "Instituto Portugues de Oncologia de Francisco Gentil" are "Drug" (82 trials), "Biological" (14 trials), "Procedure" (14 trials), "Radiation" (9 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "conventional surgery" (10 trials), "carboplatin" (9 trials), "cyclophosphamide" (9 trials), "doxorubicin hydrochloride" (9 trials) and "vincristine sulfate" (9 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Portugues de Oncologia de Francisco Gentil" are 89 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto Portugues de Oncologia de Francisco Gentil". undefined are not yet recruiting, 20 are recruiting, 13 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 50 completed trials in Instituto Portugues de Oncologia de Francisco Gentil, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Portugues de Oncologia de Francisco Gentil, 8 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 55 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".